Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

A 333-unit community, Hillcrest Apartments, will be developed directly across from Amgen’s headquarters in Thousand Oaks, ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Amgen's new weight loss drug, MariTide, shows up to 20% weight loss in trials, but faces competition from Eli Lilly and Novo ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Amgen beat Q1 estimates with strong margins driven by Blincyto, Prolia, and standout Imdelltra growth, plus strength in ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Amgen (AMGN – Research Report) yesterday. The company’s shares closed yesterday at $277.49. Confident Investing Sta ...